Target intelligence / Profile preview

V-type proton ATPase subunit S1 (ATP6AP1)

Target
ATP6AP1
Molecular classification
Enzyme, Transporter, Other
01

Overview

V-type proton ATPase subunit S1 (ATP6AP1, also known as Ac45) is an essential accessory subunit of the vacuolar-type H+-ATPase (V-ATPase) complex, a multi-subunit proton pump responsible for acidifying intracellular organelles such as lysosomes, endosomes, and secretory vesicles. ATP6AP1 plays a critical role in V-ATPase assembly, stability, and targeting to specialized subcellular compartments, thereby regulating luminal pH, vesicular trafficking, and autophagy. Dysregulation of ATP6AP1 is implicated in several human pathologies; its overexpression is associated with poor prognosis, chemoresistance, and immunosuppression in various cancers, including breast, colorectal, and hepatocellular carcinomas, while loss-of-function mutations cause a congenital disorder of glycosylation characterized by immunodeficiency, hepatopathy, and cognitive impairment. Pharmacologically, ATP6AP1 has emerged as a promising therapeutic target, with the FDA-approved drug niclosamide recently identified as a direct degrader that destabilizes ATP6AP1 to suppress tumor progression and overcome drug resistance. Additionally, classical V-ATPase inhibitors like bafilomycin A1 and concanamycin A disrupt the function of the V-complex containing ATP6AP1, highlighting its significance in therapeutic strategies targeting organelle acidification and autophagy.

Other names
ATPase H+ transporting accessory protein 1ATPase H+ transporting lysosomal accessory protein 1V-ATPase Ac45 subunitAc45Vacuolar proton pump subunit S1X-associated protein 3XAP-3ATP6S1ATP6IP1VATPS1
02

Mechanism of action

Targeted protein degradation of ATP6AP1 to suppress tumor progression and enhance chemotherapy sensitivity, or indirect inhibition of the V-ATPase proton pump complex to disrupt organelle acidification and block autophagic flux.

03

Biological functions

Acidification of intracellular organellesV-ATPase assemblyAutophagy regulationVesicular traffickingmTORC1 activationIron homeostasisOther
04

Disease associations

CancerImmunodeficiencyCongenital disorder of glycosylationNeurodegenerative diseaseOther
05

Safety considerations

Congenital disorders of glycosylation (CDG)Immunodeficiency and recurrent infectionsHepatopathy and acute liver failureCognitive impairmentSystemic toxicity from non-selective V-ATPase inhibition
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

ATP6AP1 expression levelTMEM9/ATP6AP1 ratioATP6AP1 mutation status

Beyond the preview

Go deeper on V-type proton ATPase subunit S1 (ATP6AP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on V-type proton ATPase subunit S1 (ATP6AP1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call